Clinical Trial Update: Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update on an allogeneic CD7-targeted CAR-T cell therapy for high-risk T-cell malignancies (T-cell acute lymphoblastic leukemia/lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD7 CAR-T cells (allogeneic) (CD7-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Baylor College of Medicine | Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING